{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:31:37Z","timestamp":1793442697920,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332025152"],"award-info":[{"award-number":["3332025152"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115372","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:37:19Z","timestamp":1789688239000},"page":"115372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy"],"prefix":"10.1016","volume":"399","author":[{"given":"Liqing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mong-Hsiu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingji","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2026.115372_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115372_bb0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115372_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","article-title":"Targeting STING to promote antitumor immunity","volume":"33","author":"Chin","year":"2023","journal-title":"Trends Cell Biol."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115372_bb0025","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1039\/D2CS00968D","article-title":"Immunological nanomaterials to combat cancer metastasis","volume":"53","author":"Pan","year":"2024","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS-STING pathway in cancer biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115372_bb0035","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1021\/acs.chemrev.1c00750","article-title":"Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy","volume":"122","author":"Garland","year":"2022","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12943-024-02186-6","article-title":"Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform \u2018cold\u2019 tumors into \u2018hot\u2019 tumors","volume":"23","author":"Ying","year":"2024","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115372_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103323","article-title":"Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy","volume":"9","author":"Motedayen Aval","year":"2020","journal-title":"J. Clin. Med."},{"issue":"92","key":"10.1016\/j.jconrel.2026.115372_bb0050","doi-asserted-by":"crossref","first-page":"eadj3945","DOI":"10.1126\/sciimmunol.adj3945","article-title":"STING licensing of type I dendritic cells potentiates antitumor immunity","volume":"9","author":"Wang","year":"2024","journal-title":"Sci. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115372_bb0055","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2017.52","article-title":"A STING-activating nanovaccine for cancer immunotherapy","volume":"12","author":"Luo","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115372_bb0060","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115372_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202109254","article-title":"A minimalist binary vaccine carrier for personalized postoperative cancer vaccine therapy","volume":"34","author":"Zhao","year":"2022","journal-title":"Adv. Mater."},{"issue":"6506","key":"10.1016\/j.jconrel.2026.115372_bb0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.abb4255","article-title":"Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic","volume":"369","author":"Chin","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","article-title":"STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer","volume":"119","author":"Ghaffari","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor Spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2020.06.009","article-title":"Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion","volume":"53","author":"Wu","year":"2020","journal-title":"Immunity"},{"issue":"7931","key":"10.1016\/j.jconrel.2026.115372_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","article-title":"STING-induced regulatory B cells compromise NK function in cancer immunity","volume":"610","author":"Li","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0095","doi-asserted-by":"crossref","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","article-title":"Trial watch: STING agonists in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115372_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist. Updat."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115372_bb0110","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1111\/cas.15913","article-title":"Targeting the loss of cGAS\/STING signaling in cancer","volume":"114","author":"Sasaki","year":"2023","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115372_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13092160","article-title":"STING-activating nanoparticles combined with PD-1\/PD-L1 blockade: a synergistic approach in cancer immunotherapy","volume":"13","author":"Bartusik-Aebisher","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10799893.2024.2325353","article-title":"cGAS-STING and PD1\/PDL-1 pathway in breast cancer: a window to new therapies","volume":"44","author":"Khorasani","year":"2024","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.jconrel.2026.115372_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.actbio.2025.01.038","article-title":"Facile integration of a binary nano-prodrug with \u03b1PD-L1 as a translatable technology for potent immunotherapy of TNBC","volume":"194","author":"Zhou","year":"2025","journal-title":"Acta Biomater."},{"issue":"34","key":"10.1016\/j.jconrel.2026.115372_bb0130","doi-asserted-by":"crossref","first-page":"23727","DOI":"10.1021\/acsnano.4c08613","article-title":"Metal-phenolic vehicles potentiate cycle-cascade activation of pyroptosis and cGAS-STING pathway for tumor immunotherapy","volume":"18","author":"Sun","year":"2024","journal-title":"ACS Nano"},{"issue":"6506","key":"10.1016\/j.jconrel.2026.115372_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115372_bb0140","doi-asserted-by":"crossref","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","article-title":"LBA15 -Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115372_bb0145","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0150","first-page":"56","article-title":"The roles of exosomal immune checkpoint proteins in tumors","volume":"8","author":"Xing","year":"2021","journal-title":"Mil. Med. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115372_bb0155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"10.1016\/j.jconrel.2026.115372_bb0160","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","article-title":"Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma","volume":"76","author":"Clark","year":"2016","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115372_bb0165","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","article-title":"Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy","volume":"22","author":"Gao","year":"2020","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115372_bb0170","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI133055","article-title":"A tumor-intrinsic PD-L1\/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy","volume":"130","author":"Theivanthiran","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0175","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"Challenges coexist with opportunities: spatial heterogeneity expression of PD-L1 in cancer therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115372_bb0180","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","article-title":"Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy","volume":"43","author":"Song","year":"2025","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.jconrel.2026.115372_bb0185","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr1728","article-title":"Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion","volume":"11","author":"Zhao","year":"2025","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115372_bb0190","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41419-019-2129-5","article-title":"NF-kappaB2 signalling in enteroids modulates enterocyte responses to secreted factors from bone marrow-derived dendritic cells","volume":"10","author":"Jones","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0195","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cell.2013.07.023","article-title":"Structure-function analysis of STING activation by c[G(2\u2032,5\u2032)pA(3\u2032,5\u2032)p] and targeting by antiviral DMXAA","volume":"154","author":"Gao","year":"2013","journal-title":"Cell"},{"issue":"7736","key":"10.1016\/j.jconrel.2026.115372_bb0200","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115372_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115210","article-title":"Identification of bioactive compounds and potential mechanisms of scutellariae radix-coptidis rhizoma in the treatment of atherosclerosis by integrating network pharmacology and experimental validation","volume":"165","author":"Ji","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115372_bb0210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","article-title":"Ligand docking and binding site analysis with PyMOL and Autodock\/Vina","volume":"24","author":"Seeliger","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"17","key":"10.1016\/j.jconrel.2026.115372_bb0215","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1021\/ma4011796","article-title":"Comprehensive NMR studies of the structures and properties of PEI polymers","volume":"46","author":"Holycross","year":"2013","journal-title":"Macromolecules"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115372_bb0220","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41551-020-00675-9","article-title":"Prolonged activation of innate immune pathways by a polyvalent STING agonist","volume":"5","author":"Li","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115372_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2017.08.001","volume":"147","author":"Thaker","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115372_bb0230","article-title":"Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC)","volume":"36","author":"Halachmi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0235","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/mt.2015.1","article-title":"First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings","volume":"23","author":"Buscail","year":"2015","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115372_bb0240","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1080\/21645515.2017.1285477","article-title":"Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma","volume":"13","author":"Meleshko","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0245","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/QAI.0b013e3182a99590","article-title":"Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial","volume":"64","author":"Rodriguez","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2026.115372_bb0250","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jconrel.2023.09.001","article-title":"Polyethylenimine (PEI) in gene therapy: current status and clinical applications","volume":"362","author":"Casper","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115372_bb0255","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles","volume":"7","author":"Frohlich","year":"2012","journal-title":"Int. J. Nanomedicine"},{"issue":"14","key":"10.1016\/j.jconrel.2026.115372_bb0260","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115372_bb0265","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1083\/jcb.123.5.1107","article-title":"Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation","volume":"123","author":"Wang","year":"1993","journal-title":"J. Cell Biol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115372_bb0270","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1093\/nar\/gkh595","article-title":"Gene delivery by dendrimers operates via a cholesterol dependent pathway","volume":"32","author":"Manunta","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0275","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1083\/jcb.200908086","article-title":"Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling","volume":"188","author":"Koivusalo","year":"2010","journal-title":"J. Cell Biol."},{"issue":"10066","key":"10.1016\/j.jconrel.2026.115372_bb0280","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115372_bb0285","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1002\/cam4.5676","article-title":"The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1\/PD-L1 inhibitors: a systematic review and meta-analysis","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0290","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ajcp\/aqw134","article-title":"Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer","volume":"146","author":"Li","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115372_bb0295","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2020.10.006","article-title":"The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis","volume":"79","author":"Mori","year":"2021","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0300","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115372_bb0305","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0310","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115372_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115372_bb0320","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0325","doi-asserted-by":"crossref","first-page":"1710899","DOI":"10.1080\/20013078.2019.1710899","article-title":"Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients","volume":"9","author":"Cordonnier","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.jconrel.2026.115372_bb0330","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.addr.2015.12.004","article-title":"Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines","volume":"104","author":"Park","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115372_bb0335","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/19420862.2015.1136043","article-title":"Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor","volume":"8","author":"Deng","year":"2016","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0340","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling strength determines proapoptotic functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.jconrel.2026.115372_bb0345","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115372_bb0350","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines(R) insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0355","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/cells12040530","article-title":"PD-1\/PD-L1 and DNA damage response in cancer","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.jconrel.2026.115372_bb0360","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1158\/1078-0432.CCR-24-3630","article-title":"Phase I and II clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Harrington","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"6439","key":"10.1016\/j.jconrel.2026.115372_bb0365","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"},{"issue":"7265","key":"10.1016\/j.jconrel.2026.115372_bb0370","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115372_bb0375","doi-asserted-by":"crossref","first-page":"19049","DOI":"10.1038\/srep19049","article-title":"Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"7454","key":"10.1016\/j.jconrel.2026.115372_bb0380","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature12306","article-title":"cGAS produces a 2\u2032-5\u2032-linked cyclic dinucleotide second messenger that activates STING","volume":"498","author":"Ablasser","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115372_bb0385","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115372_bb0390","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","article-title":"CD8(+) but not CD8(\u2212) dendritic cells cross-prime cytotoxic T cells in vivo","volume":"192","author":"den Haan","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115372_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100893","article-title":"Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells","volume":"39","author":"Shui","year":"2023","journal-title":"Neoplasia"},{"issue":"6013","key":"10.1016\/j.jconrel.2026.115372_bb0400","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115372_bb0405","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/641757","article-title":"Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell","volume":"2010","author":"Ito","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"issue":"5899","key":"10.1016\/j.jconrel.2026.115372_bb0410","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115372_bb0415","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.188.Supp.171.9","article-title":"Natural regulatory T cell controls physiological tolerance and regional immune privilege: studies on (C57BL\/6xA\/J) F1 (B6AF1) DEREG (\u201cdepletion of regulatory T cell\u201d) mice","volume":"188","author":"Harakal","year":"2012","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115372_bb0420","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0425","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115372_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115372_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115083","article-title":"Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer","volume":"202","author":"Mikhail","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115372_bb0440","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jaad.2024.05.095","article-title":"Current and emerging intralesional immunotherapies in cutaneous oncology","volume":"91","author":"Stull","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0445","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12864-019-6344-3","article-title":"Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors","volume":"21","author":"Zhong","year":"2020","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jconrel.2026.115372_bb0450","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1471-2407-8-228","article-title":"Imagable 4T1 model for the study of late stage breast cancer","volume":"8","author":"Tao","year":"2008","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115372_bb0455","first-page":"385","article-title":"Is tail vein injection a relevant breast cancer lung metastasis model?","volume":"5","author":"Rashid","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.jconrel.2026.115372_bb0460","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2407-12-120","article-title":"A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease","volume":"12","author":"Kaur","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2026.115372_bb0465","first-page":"19.2.1","article-title":"Tail vein assay of cancer metastasis","volume":"19","author":"Elkin","year":"2001","journal-title":"Curr. Protoc. Cell Biol. Chapter"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115372_bb0470","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/biomedicines13092160","article-title":"STING-activating nanoparticles combined with PD-1\/PD-L1 blockade: a synergistic approach in cancer immunotherapy","volume":"13","author":"Bartusik-Aebisher","year":"2025","journal-title":"Biomedicines"},{"issue":"24","key":"10.1016\/j.jconrel.2026.115372_bb0475","article-title":"Dysfunctional T cell reprogramming via cascade-responsive catalytic nanosponges-mediated tumor-specific antigen capture for remote glioblastoma immunotherapy","volume":"36","author":"Huynh","year":"2025","journal-title":"Adv. Funct. Mater."},{"issue":"27","key":"10.1016\/j.jconrel.2026.115372_bb0480","doi-asserted-by":"crossref","first-page":"25134","DOI":"10.1021\/acsnano.5c05395","article-title":"Reprogramming immunodeficiency in lung metastases via PD-L1 siRNA delivery and antigen capture of nanosponge-mediated dendritic cell modulation","volume":"19","author":"Huynh","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115372_bb0485","first-page":"291","article-title":"Long-distance modulation of bystander tumor cells by CD8(+) T-cell-secreted IFN-gamma","volume":"1","author":"Hoekstra","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2026.115372_bb0490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"7029","key":"10.1016\/j.jconrel.2026.115372_bb0500","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature03337","article-title":"CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death","volume":"434","author":"Janssen","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115372_bb0505","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41585-023-00834-y","article-title":"Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer","volume":"21","author":"S\u00e9guier","year":"2024","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115372_bb0510","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232654","article-title":"Intratumoral injection of immunotherapeutics: state of the art and future directions","volume":"312","author":"Sheth","year":"2024","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115372_bb0515","article-title":"Disruption of zinc homeostasis by a novel platinum(IV)-terthiophene complex for antitumor immunity","volume":"62","author":"Su","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115372_bb0520","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1021\/acs.accounts.0c00518","article-title":"Tumor-targeted nanomedicine for immunotherapy","volume":"53","author":"Cabral","year":"2020","journal-title":"Acc. Chem. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:47:09Z","timestamp":1793440029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926007765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":104,"alternative-id":["S0168365926007765"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115372","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115372"}}